Royalty Pharma lifts 2026 outlook amid strong cash flows
Tip Ranks·- Royalty Pharma reported strong second-quarter financial results for 2026, highlighted by a 14 % increase in quarterly revenue to $ 773 million and an upgraded full-year portfolio revenue guidance of $ 3.4 billion to $ 3.5 billion. - The company leveraged robust cash generation and a cash conversion rate of approximately 95 % to deploy $ 1.1 billion into royalty acquisitions and return about $ 370 million to shareholders through dividends and buybacks. - Management acknowledged product-specific headwinds and declining milestone revenues, yet emphasized that strategic transactions like the cliramitug acquisition position the firm for continued growth.